Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Aparna Nallagangula
Assistant Clinical Professor, Medicine - (Clinical Series Track)
Medicine
Overview
Research
More
Collaboration
(4)
Clara Curiel
Mutual work: 1 Grant﹒1 Proposal
Collaboration Details
Jennifer Segar
Mutual work: 2 Proposals﹒1 Grant
Collaboration Details
Brianna Denton
Mutual work: 2 Proposals﹒1 Grant
Collaboration Details
Octavio Castanos
Mutual work: 2 Proposals﹒1 Grant
Collaboration Details
Grants
(8)
A Phase 1/2 Open-Label, Multicenter, Global Trial to Characterize the Safety, Tolerability and Preliminary Efficacy of CFT1946 as a Monotherapy and in Combination with Trametinib in Subjects with BRAF
Active
·
2024
·
$433.9K
·
External
Principal Investigator (PI)
drug development,
oncology,
clinical trials,
pharmacology,
precision medicine
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/relapsed, Unresectable Stage III or IV Melanoma
Active
·
2021
·
$971.6K / $485.8K
·
External
Principal Investigator (PI)
immunotherapy,
melanoma,
clinical trial,
combination therapy,
cancer treatment
A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Active
·
2020
·
$1.5M
·
External
Principal Investigator (PI)
immunotherapy,
melanoma,
combination therapy,
solid tumors,
clinical trial
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma
Active
·
2020
·
$265.4K
·
External
Principal Investigator (PI)
immunotherapy,
melanoma,
adjuvant therapy,
clinical trial,
cancer treatment
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study
Active
·
2019
·
$394K
·
External
Principal Investigator (PI)
immunotherapy,
melanoma,
clinical trial,
adjuvant therapy,
cancer treatment
Page 1 of 2
Previous page
Next page
Publications
(1)
Recent
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma
2022
immunotherapy,
skin cancer,
cancer treatment,
clinical trials,
cancer immunology